{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:07:29Z","timestamp":1758931649658,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["105-2218-E-006-016-MY2","105-2218-E-006-016-MY2","105-2218-E-006-016-MY2"],"award-info":[{"award-number":["105-2218-E-006-016-MY2","105-2218-E-006-016-MY2","105-2218-E-006-016-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2221-E-006-186","111-2221-E-006-186"],"award-info":[{"award-number":["111-2221-E-006-186","111-2221-E-006-186"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>As we emerge from the COVID-19 pandemic and transition to a post-pandemic era, it is crucial to reflect on our experiences and prepare for future pandemics. Here we evaluate the impact of different methods for calculating the vaccine efficacy of COVID-19 vaccines, which has not been done previously.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a meta-analysis of 38 approved COVID-19 vaccines using data from phase III clinical trials between May 4, 2020, and June 10, 2022. We analyze vaccine efficacy against multiple SARS-CoV-2 variants including the original strain, Alpha, Beta, Delta, and Kappa using multiple endpoints. Clinical endpoints are categorized into a tree structure including asymptomatic infection, symptomatic infection, mild to critical illness, and death. We employ re-estimated vaccine efficacies, including relative risk and Poisson regression with robust error variance, for equitable cross-vaccine comparisons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We re-estimated 63 vaccine efficacies, revealing a 3% to 6% difference in five efficacies compared to the original study. Four efficacies exhibited lower bounds below the critical 50% threshold for the endpoint asymptomatic, symptomatic, moderate, and severe, contrary to the initial reports. However, efficacy consistently surpasses the 50% threshold against symptomatic COVID-19. Overall efficacies range from 34.2% to 100%, 50.3% to 100% against symptomatic, and 66.8% to 100% against severe, and 65% to 95% against variants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our systematic classification of vaccine endpoints enables more statistically rigorous meta-analyses across studies. Beyond the quantitative results, our study emphasizes the need to standardize the estimation method for robust assessments of vaccine efficacy. We highlight the incompleteness of the knowledge about different vaccine efficacy in the middle of the pandemic, in particular the need to identify variants during the trials and report on multiple endpoints. We encourage all authors to publicly share their data, fostering additional impartial investigations. This data collection enables comparisons with real-world effectiveness data, enabling future studies of the predictive power of efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-11289-4","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:37:31Z","timestamp":1758883051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A meta-analysis of vaccine efficacy from phase III clinical trials of approved vaccines against SARS-CoV-2 and variants"],"prefix":"10.1186","volume":"25","author":[{"given":"Dipesh","family":"Dhayfule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Heng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Ashyani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Shiang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torbj\u00f6rn\u00a0E.\u00a0M.","family":"Nordling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"10309","key":"11289_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","volume":"398","author":"SY Tartof","year":"2021","unstructured":"Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407\u201316.","journal-title":"Lancet."},{"key":"11289_CR2","unstructured":"NCCID. Updates on COVID-19 Variants of Concern. 2021.\u00a0https:\/\/nccid.ca\/covid-19-variants\/. Accessed 27 Apr 2021."},{"issue":"3","key":"11289_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/vaccines9030243","volume":"9","author":"CE G\u00f3mez","year":"2021","unstructured":"G\u00f3mez CE, Perdiguero B, Esteban M. Emerging sars-cov-2 variants and impact in global vaccination programs against sars-cov-2\/covid-19. Vaccines. 2021;9(3):243.","journal-title":"Vaccines."},{"issue":"6","key":"11289_CR4","first-page":"100959","volume":"40","author":"Y Kherabi","year":"2021","unstructured":"Kherabi Y, Fiolet T, Rozencwajg S, Sala\u00fcn JP, Peiffer-Smadja N. COVID-19 vaccine boosters: What do we know so far? Anaesth Crit Care Pain Med. 2021;40(6):100959.","journal-title":"Anaesth Crit Care Pain Med."},{"key":"11289_CR5","unstructured":"Hasan SAW. Interim statement on COVID-19 vaccine booster doses. 2021.\u00a0https:\/\/www.who.int\/news\/item\/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses. Accessed 30 Jun 2025."},{"issue":"1","key":"11289_CR6","first-page":"225","volume":"28","author":"MN Zahid","year":"2021","unstructured":"Zahid MN, Moosa MS, Perna S, Buti EB. A review on COVID-19 vaccines: stages of clinical trials, mode of actions and efficacy. Arab J Basic Appl Sci. 2021;28(1):225\u201333.","journal-title":"Arab J Basic Appl Sci."},{"key":"11289_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"10","author":"JS Tregoning","year":"2021","unstructured":"Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;10:626\u201336.","journal-title":"Nat Rev Immunol."},{"issue":"9","key":"11289_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/vaccines9090989","volume":"9","author":"YJ Fan","year":"2021","unstructured":"Fan YJ, Chan KH, Hung IFN. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines. 2021;9(9):989.","journal-title":"Vaccines."},{"issue":"6","key":"11289_CR9","doi-asserted-by":"publisher","first-page":"ofac138","DOI":"10.1093\/ofid\/ofac138","volume":"9","author":"MM Higdon","year":"2022","unstructured":"Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease. Open Forum Infectious Diseases. 2022;9(6):ofac138.","journal-title":"Open Forum Infectious Diseases."},{"issue":"1","key":"11289_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12941-022-00525-3","volume":"21","author":"M Sobczak","year":"2022","unstructured":"Sobczak M, Pawliczak R. COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. Ann Clin Microbiol Antimicrob. 2022;21(1):32.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"4","key":"11289_CR11","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/S2666-5247(22)00390-1","volume":"4","author":"ZR Yang","year":"2023","unstructured":"Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4(4):e236\u201346.","journal-title":"Lancet Microbe."},{"key":"11289_CR12","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg."},{"issue":"10317","key":"11289_CR13","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","volume":"398","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173\u201384.","journal-title":"Lancet."},{"key":"11289_CR14","doi-asserted-by":"publisher","unstructured":"Palacios R, Batista AP, Albuquerque CSN, Pati\u00f1o EG, do\u00a0Prado\u00a0Santos J, Conde MTRP, et\u00a0al. Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study. SSRN Electronic Journal. 2021.\u00a0https:\/\/papers.ssrn.com\/abstract=3822780.https:\/\/doi.org\/10.2139\/SSRN.3822780.","DOI":"10.2139\/SSRN.3822780"},{"issue":"19","key":"11289_CR15","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","volume":"385","author":"HM El Sahly","year":"2021","unstructured":"El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774\u201385.","journal-title":"N Engl J Med."},{"issue":"5","key":"11289_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med."},{"issue":"10321","key":"11289_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"SA Halperin","year":"2022","unstructured":"Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237\u201348.","journal-title":"Lancet."},{"key":"11289_CR18","first-page":"100423","volume":"18","author":"ME Toledo-Roman\u00ed","year":"2023","unstructured":"Toledo-Roman\u00ed ME, Garc\u00eda-Carmenate M, Valenzuela-Silva C, Baldoqu\u00edn-Rodr\u00edguez W, Mart\u00ednez-P\u00e9rez M, Rodr\u00edguez-Gonz\u00e1lez M, et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. Lancet Reg Health Am. 2023;18:100423.","journal-title":"Lancet Reg Health Am."},{"issue":"27","key":"11289_CR19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med."},{"key":"11289_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"1","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021;1:35\u201345.","journal-title":"JAMA."},{"issue":"19","key":"11289_CR21","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","volume":"385","author":"SJ Thomas","year":"2021","unstructured":"Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761\u201373.","journal-title":"N Engl J Med."},{"issue":"3","key":"11289_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2107456","volume":"385","author":"RW Frenck Jr","year":"2021","unstructured":"Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239\u201350.","journal-title":"N Engl J Med."},{"issue":"20","key":"11289_CR23","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","volume":"386","author":"ED Moreira Jr","year":"2022","unstructured":"Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med. 2022;386(20):1910\u201321.","journal-title":"N Engl J Med."},{"issue":"12","key":"11289_CR24","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","volume":"22","author":"K Hardt","year":"2022","unstructured":"Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22(12):1703\u201315.","journal-title":"Lancet Infect Dis."},{"issue":"22","key":"11289_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"L Dai","year":"2022","unstructured":"Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N Engl J Med. 2022;386(22):2097\u2013111.","journal-title":"N Engl J Med."},{"issue":"22","key":"11289_CR26","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1056\/NEJMoa2201300","volume":"386","author":"KJ Hager","year":"2022","unstructured":"Hager KJ, P\u00e9rez Marc G, Gobeil P, Diaz RS, Heizer G, Llapur C, et al. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. N Engl J Med. 2022;386(22):2084\u201396.","journal-title":"N Engl J Med."},{"issue":"10296","key":"11289_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover MD, Do\u011fanay HL, Akova M, G\u00fcner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213\u201322.","journal-title":"Lancet."},{"issue":"10332","key":"11289_CR28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","volume":"399","author":"A Khobragade","year":"2022","unstructured":"Khobragade A, Bhate S, Ramaiah V, Deshpande S, Giri K, Phophle H, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399(10332):1313\u201321.","journal-title":"Lancet."},{"issue":"10275","key":"11289_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671\u201381.","journal-title":"Lancet."},{"issue":"25","key":"11289_CR30","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348\u201360.","journal-title":"N Engl J Med."},{"key":"11289_CR31","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"23","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. N Engl J Med. 2021;23:2187\u2013201.","journal-title":"N Engl J Med."},{"issue":"10282","key":"11289_CR32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KR Emary","year":"2021","unstructured":"Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351\u201362.","journal-title":"Lancet."},{"issue":"10277","key":"11289_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881\u201391.","journal-title":"Lancet."},{"issue":"13","key":"11289_CR34","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172\u201383.","journal-title":"N Engl J Med."},{"issue":"10269","key":"11289_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet."},{"issue":"6","key":"11289_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2116185","volume":"386","author":"LM Dunkle","year":"2022","unstructured":"Dunkle LM, Kotloff KL, Gay CL, \u00c1\u00f1ez G, Adelglass JM, Barrat Hern\u00e1ndez AQ, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022;386(6):531\u201343.","journal-title":"N Engl J Med."},{"key":"11289_CR37","doi-asserted-by":"publisher","unstructured":"Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol. 1987;125(5):761\u20138. Google Scholar citations: 1,980 (checked 2025-02-26); Highly cited.\u00a0https:\/\/academic.oup.com\/aje\/article-abstract\/125\/5\/761\/166189.https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114593.","DOI":"10.1093\/oxfordjournals.aje.a114593"},{"key":"11289_CR38","doi-asserted-by":"publisher","unstructured":"Schmidt CO, Kohlmann T. When to use the odds ratio or the relative risk? Int J Public Health. 2008;53(3):165\u20137. Google Scholar citations: 435 (checked 2025-02-26).\u00a0https:\/\/link.springer.com\/article\/10.1007\/s00038-008-7068-3.https:\/\/doi.org\/10.1007\/s00038-008-7068-3.","DOI":"10.1007\/s00038-008-7068-3"},{"key":"11289_CR39","unstructured":"Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991. Google Scholar citations: 47,852 (checked 2025-02-26); Highly cited.\u00a0https:\/\/archive.org\/details\/practicalstatist0000altm."},{"key":"11289_CR40","doi-asserted-by":"publisher","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136. Google Scholar citations: 5,865 (checked 2025-02-26); Highly cited.\u00a0https:\/\/academic.oup.com\/aje\/article\/159\/7\/702\/71883.https:\/\/doi.org\/10.1093\/aje\/kwh090.","DOI":"10.1093\/aje\/kwh090"},{"key":"11289_CR41","doi-asserted-by":"publisher","unstructured":"Pagano M, Gauvreau K, Mattie H. Principles of Biostatistics. 3rd ed. Belmont: Chapman & Hall\/CRC; 2022. Google Scholar citations for all editions: [CDATA[>]]$$>$$5,600 (checked 2025-02-26); Highly cited.\u00a0https:\/\/www.routledge.com\/Principles-of-Biostatistics\/Pagano-Gauvreau-Mattie\/p\/book\/9780367345525.https:\/\/doi.org\/10.1201\/9780429340512.","DOI":"10.1201\/9780429340512"},{"issue":"1","key":"11289_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12874-022-01673-y","volume":"22","author":"S Masoumi","year":"2022","unstructured":"Masoumi S, Shahraz S. Meta-analysis using Python: a hands-on tutorial. BMC Med Res Methodol. 2022;22(1):193.","journal-title":"BMC Med Res Methodol."},{"key":"11289_CR43","doi-asserted-by":"publisher","unstructured":"Shrestha Y, Venkataraman R, Moktan JB, Chitti R, Yadav SK. COVID-19 Vaccine Authorized in India-A Mini Review. SSRN Electron J. 2021.\u00a0https:\/\/papers.ssrn.com\/abstract=3836545.https:\/\/doi.org\/10.2139\/SSRN.3836545.","DOI":"10.2139\/SSRN.3836545"},{"issue":"10269","key":"11289_CR44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","volume":"397","author":"MD Knoll","year":"2021","unstructured":"Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72\u20134.","journal-title":"Lancet."},{"key":"11289_CR45","doi-asserted-by":"publisher","first-page":"101218","DOI":"10.1016\/j.eclinm.2021.101218","volume":"42","author":"PS Kulkarni","year":"2021","unstructured":"Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, et al. A phase 2\/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021;42:101218.","journal-title":"EClinicalMedicine."},{"key":"11289_CR46","doi-asserted-by":"publisher","first-page":"101126","DOI":"10.1016\/j.eclinm.2021.101126","volume":"40","author":"S Gonz\u00e1lez","year":"2021","unstructured":"Gonz\u00e1lez S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Mar\u00edn L, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60\u201379: a retrospective cohort study in Argentina. EClinicalMedicine. 2021;40:101126.","journal-title":"EClinicalMedicine."},{"key":"11289_CR47","unstructured":"Nicole E Basta. McGill University COVID19 Vaccine Tracker. 2021.\u00a0https:\/\/covid19.trackvaccines.org\/our-team\/. Accessed 10 June 2022."},{"key":"11289_CR48","unstructured":"An international randomised trial of candidate vaccines against COVID-19. 2020.\u00a0https:\/\/www.who.int\/publications\/i\/item\/an-international-randomised-trial-of-candidate-vaccines-against-covid-19. Accessed 15 Jan 2025."},{"key":"11289_CR49","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"342","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Bmj. 2011;342:d4002.","journal-title":"Bmj."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11289-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11289-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:37:34Z","timestamp":1758883054000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11289-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11289"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11289-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1169"}}